Government-Owned Inventions; Availability for Licensing, 42823-42824 [2017-19313]
Download as PDF
<![CDATA[
42823
Federal Register / Vol. 82, No. 175 / Tuesday, September 12, 2017 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
responses per
respondent
Number of
respondents
Form name
Total
responses
Average burden
per response
(in hours)
Total burden
hours
(rounded up)
Missing Report Form .........................................................
Subject Statement and Dispute .........................................
Request for Dispute Resolution .........................................
Electronic Transfer of Funds (EFT) Authorization .............
Authorized Agent Designation ...........................................
Account Discrepancy .........................................................
New Administrator Request ...............................................
Query Credit Purchase ......................................................
Educational Request ..........................................................
Account Balance Transfer .................................................
29
3,547
99
654
213
10
3,016
789
10
10
1
1
1
1
1
1
1
1
1
1
29
3,547
99
654
213
10
3,016
789
10
10
.08
.75
8
.08
.25
.25
.08
.08
.08
.08
3
2,661
792
53
54
3
242
64
1
1
Total ............................................................................
6,059,761
........................
6,059,761
..........................
326,120
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2017–19252 Filed 9–11–17; 8:45 am]
BILLING CODE 4165–15–P
Dated: September 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2017–19232 Filed 9–11–17; 8:45 am]
pmangrum on DSK3GDR082PROD with NOTICES1
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meeting
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Developmental Biology
Subcommittee.
VerDate Sep<11>2014
15:19 Sep 11, 2017
Jkt 241001
Date: October 2, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda Downtown,
7335 Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Cathy J. Wedeen, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, OD, Eunice Kennedy
Shriver National Institute of Child Health
and Human Development, NIH, DHHS, 6710
B Rockledge Drive, Bethesda, Maryland
20892, 301–435–6878, wedeenc@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
Government owned
intellectual property covering imaging
agents with improved renal clearance
available for licensing and
commercialization.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by emailing the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Transfer and Development Office of
Technology Transfer, 31 Center Drive,
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION: The
inventions listed below are owned by an
agency of the U.S. Government and are
available for licensing in the U.S. in
accordance with 35 U.S.C. 209 and 37
CFR part 404 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing. A description of the
technology available for licensing
follows.
Evans Blue Dye Derivatives for Serum
Albumin Labeling
Description of Technology: The
invention is an imaging agent and
method of its use for imaging blood
pools and the lymphatic system. The
imaging agent binds with high affinity
to serum albumin, the most abundant
serum protein, and can be tagged with
several isotopes making it suitable for
magnetic resonance imaging or positron
emission tomographic imaging. To date,
only very few blood-pool tracers have
been introduced for positron emission
tomography. The existing ones have
short half-lives (20.4 min for 11C and
2.05 min for 15O) and thus can only be
used in centers with an in-house
cyclotron. Compared with these
radiometals, 18F has the advantages of
being a pure position emitter with ideal
half-life. It is the dominant radioisotope
used for PET imaging for both clinical
applications and preclinical
investigations. Evans blue dye has been
an important tool in many physiological
and clinical investigations because of its
E:\FR\FM\12SEN1.SGM
12SEN1
42824
Federal Register / Vol. 82, No. 175 / Tuesday, September 12, 2017 / Notices
high affinity for plasma albumin and
has been used for a long time in clinical
practice for determination of patient
plasma volume. The current imaging
agent is a truncated form of EB [NEB])
and has the ability to bind albumin with
high affinity. The agent is also
conjugated to NOTA to enable in vivo
labeling with 18F labeling by the
formation of 18F-aluminum fluoride
complex. The NOTA also facilitates
radiometal labeling of NEB with either
68Ga or 64Cu. The resulting imaging
agent does not affect the in vivo
behavior of serum albumin such as
circulation, extra-vascularization, and
turn-over; thus the imaging results will
reflect the distribution and metabolism
of serum albumin accurately.
Potential Commercial Applications:
• Blood pool imaging.
• Lymphatic system imaging.
Development Stage:
• In vivo data available.
Inventors: Xiaoyuan Chen, Lixin Lang,
Gang Niu (all of NIBIB).
Intellectual Property: HHS Reference
No. E–099–2015/0–US–01 and/0–US–
02.
• U.S. Patent Applications
14/675,364 filed March 31, 2015 and
15/587,948 filed May 5, 2017.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@nih.gov.
Collaborative Research Opportunity:
The National Institute of Environmental
Health Sciences seeks statements of
capability or interest from parties
interested in collaborative research to
further develop and evaluate, please
contact Cecilia Pazman, Office of
Technology Transfer, National Heart,
Lung and Blood Institute, pazmance@
nhlbi.nih.gov, 301–594–4273.
Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2017–19313 Filed 9–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
pmangrum on DSK3GDR082PROD with NOTICES1
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
VerDate Sep<11>2014
15:19 Sep 11, 2017
Jkt 241001
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Shared
Instrumentation Grants for Flow Cytometers.
Date: September 26, 2017.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jonathan Arias, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7840, Bethesda, MD 20892, 301–435–
2406, ariasj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Shared and
High-End Mass Spectrometers.
Date: September 28–29, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudha Veeraraghavan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–435–1504,
sudha.veeraraghavan@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Nursing and Related Clinical Sciences Study
Section.
Date: October 2–3, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Rafael Semansky, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2040M,
Bethesda, MD 20892, 301–496–5749,
semanskyrm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Clinical
Studies in Kidney Diseases (PAR–15–161).
Date: October 2, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Atul Sahai, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
MSC 7818, Bethesda, MD 20892, 301–435–
1198, sahaia@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19230 Filed 9–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Resource
Centers for Minority Aging Research
(RCMAR) ZAG1 ZIJ–9 J1.
Date: October 31–November 1, 2017.
Time: 5:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Carmen Moten, Ph.D.,
MPH, Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703, cmoten@
mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Resource
Centers for Minority Aging Research
(RCMAR) ZAG1 ZIJ–9 J3.
Date: October 31–November 1, 2017.
Time: 5:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Carmen Moten, Ph.D.,
MPH, Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703, cmoten@
mail.nih.gov.
E:\FR\FM\12SEN1.SGM
12SEN1
]]>Agencies
[Federal Register Volume 82, Number 175 (Tuesday, September 12, 2017)]
[Notices]
[Pages 42823-42824]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19313]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Government owned intellectual property covering imaging agents
with improved renal clearance available for licensing and
commercialization.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by emailing the
indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: The inventions listed below are owned by an
agency of the U.S. Government and are available for licensing in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing. A description of the technology available for
licensing follows.
Evans Blue Dye Derivatives for Serum Albumin Labeling
Description of Technology: The invention is an imaging agent and
method of its use for imaging blood pools and the lymphatic system. The
imaging agent binds with high affinity to serum albumin, the most
abundant serum protein, and can be tagged with several isotopes making
it suitable for magnetic resonance imaging or positron emission
tomographic imaging. To date, only very few blood-pool tracers have
been introduced for positron emission tomography. The existing ones
have short half-lives (20.4 min for \11\C and 2.05 min for \15\O) and
thus can only be used in centers with an in-house cyclotron. Compared
with these radiometals, \18\F has the advantages of being a pure
position emitter with ideal half-life. It is the dominant radioisotope
used for PET imaging for both clinical applications and preclinical
investigations. Evans blue dye has been an important tool in many
physiological and clinical investigations because of its
[[Page 42824]]
high affinity for plasma albumin and has been used for a long time in
clinical practice for determination of patient plasma volume. The
current imaging agent is a truncated form of EB [NEB]) and has the
ability to bind albumin with high affinity. The agent is also
conjugated to NOTA to enable in vivo labeling with \18\F labeling by
the formation of \18\F-aluminum fluoride complex. The NOTA also
facilitates radiometal labeling of NEB with either \68\Ga or \64\Cu.
The resulting imaging agent does not affect the in vivo behavior of
serum albumin such as circulation, extra-vascularization, and turn-
over; thus the imaging results will reflect the distribution and
metabolism of serum albumin accurately.
Potential Commercial Applications:
Blood pool imaging.
Lymphatic system imaging.
Development Stage:
In vivo data available.
Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu (all of NIBIB).
Intellectual Property: HHS Reference No. E-099-2015/0-US-01 and/0-
US-02.
U.S. Patent Applications 14/675,364 filed March 31, 2015
and 15/587,948 filed May 5, 2017.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@nih.gov.
Collaborative Research Opportunity: The National Institute of
Environmental Health Sciences seeks statements of capability or
interest from parties interested in collaborative research to further
develop and evaluate, please contact Cecilia Pazman, Office of
Technology Transfer, National Heart, Lung and Blood Institute,
pazmance@nhlbi.nih.gov, 301-594-4273.
Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-19313 Filed 9-11-17; 8:45 am]
BILLING CODE 4140-01-P
